Loading…
Ocular Therapeutix, Inc. is projected to rise to $11.87 by 2027, a +15% move from its current price of $10.28. OCUL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $10.00 | $10.28 | $10.57 | -0.01% |
| Jul 13 | $9.88 | $10.28 | $10.69 | -0.01% |
| Jul 14 | $9.80 | $10.28 | $10.78 | -0.02% |
| Jul 15 | $9.72 | $10.28 | $10.86 | -0.03% |
| Jul 16 | $9.66 | $10.28 | $10.94 | -0.03% |
| Jul 17 | $9.60 | $10.28 | $11.00 | -0.04% |
| Jul 18 | $9.55 | $10.28 | $11.06 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.55 | $10.28 | $11.06 | -0.05% |
| Week 2 | $9.26 | $10.27 | $11.40 | -0.09% |
| Week 3 | $9.04 | $10.27 | $11.66 | -0.14% |
| Week 4 | $8.86 | $10.26 | $11.89 | -0.19% |
| Week 5 | $8.70 | $10.26 | $12.09 | -0.23% |
| Week 6 | $8.56 | $10.25 | $12.27 | -0.28% |
| Week 7 | $8.44 | $10.25 | $12.45 | -0.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocular Therapeutix, Inc. is a biopharmaceutical company that develops and commercializes therapies for retinal diseases and other eye conditions in the United States, using its bioresorbable hydrogel-based formulation technology. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc.
was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL is the stock for Ocular Therapeutix, Inc., currently priced at $10.33 with a market capitalization of $2.26B and ranking 1958. The stock sits in a near-term technical setup with a bullish tilt, supported by a 30-day range of $8.53 to $12.51 and a technical profile that includes RSI of 60, SMA50 of $9.16, and SMA200 of $10.35. Key nearby levels are support at $8.16 and resistance at $10.33, with volatility indicated at 60% annualized.
Longer-term forecast highlights a rising trajectory, with 2026–2050 projections showing increasing average prices and substantial ROIs, notably reaching the 2030 average of $17.04 and ROI of 65, the 2040 average of $41.31 and ROI of 299.9, and the 2050 average of $90.07 and ROI of 771.9. The forecast also shows mid-term growth through 2027–2029, before accelerating in the 2030s and beyond.
A major floor 29.4% below — a decisive break under it would weaken the trend.
The nearest floor, 20.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 16.9% above — clearing it would confirm fresh momentum.
Key OCUL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCUL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $10.20 | Buy | $10.19 | Buy |
| MA 10 | $9.97 | Buy | $10.02 | Buy |
| MA 20 | $9.70 | Buy | $9.73 | Buy |
| MA 50 | $9.21 | Buy | $9.39 | Buy |
| MA 100 | $9.05 | Buy | $9.46 | Buy |
| MA 200 | $10.32 | Sell | $9.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.75 | Neutral |
| Stoch RSI (14) | 49.81 | Neutral |
| CCI (20) | 85.60 | Neutral |
| Williams %R (14) | -31.78 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 0.84 | Buy |
| Bollinger %B (20,2) | 0.75 | Neutral |
| Stochastic %K (14) | 68.22 | Neutral |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | 0.98 | Buy |
| Ultimate (7,14,28) | 60.52 | Neutral |
| Momentum (10) | 0.44 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 10.52 | Sell |
| ADX (14) | 18.14 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is bullish, with RSI14 at 60 and a price setup shaped by the SMA50 at $9.16 and the SMA200 at $10.35. The stock is trading near the resistance line of $10.33 and above the near-term support of $8.16. The 30-day range runs from $8.53 to $12.51, signaling a move that could test the $10.33 resistance or retreat toward support if momentum wanes.
Overall near term, the stock carries higher volatility, reflected by an annualized volatility of 60%. This environment can offer upside potential if the stock sustains above the current levels, but downside risk remains tied to broader market and sector sentiment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.88 | $10.28 | $13.49 | 0% | Neutral | |
| $9.43 | $11.87 | $15.81 | +15% | Neutral | |
| $9.52 | $12.32 | $17.04 | +20% | Neutral | |
| $9.86 | $13.07 | $18.61 | +27% | Bullish | |
| $11.81 | $15.99 | $23.34 | +56% | Bullish | |
| $13.97 | $19.26 | $28.72 | +87% | Bullish | |
| $14.98 | $21.03 | $31.97 | +105% | Bullish | |
| $15.16 | $21.64 | $33.48 | +111% | Bullish | |
| $15.74 | $22.83 | $35.89 | +122% | Bullish | |
| $16.79 | $24.71 | $39.43 | +140% | Bullish | |
| $23.61 | $37.22 | $63.23 | +262% | Bullish | |
| $44.79 | $79.48 | $147.87 | +673% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.88 | $10.28 | $12.46 | +0.00% |
| August 2026 | $8.85 | $10.46 | $12.69 | +1.72% |
| September 2026 | $8.59 | $10.22 | $12.54 | -2.29% |
| October 2026 | $8.65 | $10.35 | $12.82 | +1.32% |
| November 2026 | $8.92 | $10.73 | $13.40 | +3.64% |
| December 2026 | $8.87 | $10.72 | $13.49 | -0.05% |
Click any year to see its month-by-month OCUL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, OCUL could reach as high as $13.49, with a base case around $10.28 and support toward $6.88 — roughly 0% from $10.28. Price action looks broadly range-bound.
Expect OCUL to range from $9.43 to $15.81 through 2027. The $11.87 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The OCUL price prediction for 2028 points to an average of $12.32 (low $9.52, high $17.04) — a potential gain of +20% on today's $10.28. Price action looks broadly range-bound.
In 2029, OCUL is projected to trade between $9.86 and $18.61, averaging $13.07 — a potential gain of +27% from today's $10.28. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Ocular Therapeutix, Inc.'s 2030 outlook centres on $15.99, within a $11.81 to $23.34 range. That is up +22% on the projected 2029 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2031, OCUL could reach as high as $28.72, with a base case around $19.26 and support toward $13.97 — roughly +87% from $10.28. Buyers look set to stay in control over this stretch.
Expect OCUL to range from $14.98 to $31.97 through 2032. The $21.03 average target implies a +105% move from current prices. That is up +9% on the projected 2031 average. Momentum favours further upside here.
The OCUL price prediction for 2033 points to an average of $21.64 (low $15.16, high $33.48) — a potential gain of +111% on today's $10.28. Buyers look set to stay in control over this stretch.
In 2034, OCUL is projected to trade between $15.74 and $35.89, averaging $22.83 — a potential gain of +122% from today's $10.28. That is up +5% on the projected 2033 average. Momentum favours further upside here.
Ocular Therapeutix, Inc.'s 2035 outlook centres on $24.71, within a $16.79 to $39.43 range. That is up +8% on the projected 2034 average. That marks a +140% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, OCUL could reach as high as $63.23, with a base case around $37.22 and support toward $23.61 — roughly +262% from $10.28. Momentum favours further upside here.
Expect OCUL to range from $44.79 to $147.87 through 2050. The $79.48 average target implies a +673% move from current prices. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCUL today (≈ 97.276265 OCUL) could be worth
$7,731.81
+$6,731.81 (+673%) by 2050 · US Dollar
Based on the average projected OCUL price of $79.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCULwould be worth at today's price.
$1,000 invested in OCUL on Jul 10, 2025 (≈ 90.252708 OCUL) would be worth
$927.8
-$72.2 (-7.2%) today · 0.93× · US Dollar
Based on a OCUL entry price of $11.08 vs. today's $10.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.64 | $1,066.39 | +6.6% |
| 1 month ago | $8.74 | $1,176.2 | +17.6% |
| 3 months ago | $8.79 | $1,169.51 | +17.0% |
| 6 months ago | $10.69 | $961.65 | -3.8% |
| 1 year ago | $11.08 | $927.8 | -7.2% |
| All time (5.0y) ago | $13.31 | $772.35 | -22.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCUL forecast.
Our base-case forecast reaches $21.00 around 2032.
Implied market cap at $21.00: $4.6B
Across the multi-year forecast, OCUL shows a clear bullish trajectory. By 2030, the average price is projected at $17.04 with an ROI of 65, and the price could reach a maximum of $25.10 as part of the forecast range. The outlook continues to improve into 2040, with an average of $41.31 and an ROI of 299.9, and a maximum forecast of $71.16.
By 2050, the average is projected to $90.07 with an ROI of 771.9 and a maximum of $170.35.
Earlier years in the forecast show a gradual rise in the average price and momentum turning from neutral to bullish, with 2027–2029 projecting higher averages and meaningful gains (e.g., 2027 avg $12.12, ROI 17.3; 2028 avg $12.70, ROI 22.9; 2029 avg $13.55, ROI 31.1). The longer horizon depicts substantial upside potential, though these are estimates, not guarantees, and should be considered in the context of market risk and the inherent uncertainty of future prices.
Tap a question to reveal the answer.
The forecast shows an average price of $17.04 with a maximum of $25.10 and a minimum of $12.49, with a predicted ROI of 65 and a bullish sentiment.
Forecasts indicate a bullish trajectory beyond 2026, with the 2030 average at $17.04 and ROI of 65, the 2040 average at $41.31 and ROI of 299.9, and the 2050 average at $90.07 and ROI of 771.9. These are estimates, not guarantees.
Yes. The 2040 forecast shows a maximum of $71.16, and the 2050 forecast shows a maximum of $170.35, so reaching $50 appears possible within the 2040–2050 window.
The 30-day range is $8.53 to $12.51.
The current price is $10.33 and the market cap is $2.26B.
Ocular Therapeutix, Inc. Community Discussion
0Share your Ocular Therapeutix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.